PAS
AVIR icon

Point72 Asia (Singapore)’s Atea Pharmaceuticals AVIR Stock Holding History

Point72 Asia (Singapore)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$10.4K Buy
+3,601
New +$12.3K ﹤0.01% 775
2024
Q3 		– Sell
-3,028
Closed -$10K – 967
2024
Q2 		$10K Sell
3,028
-2,472
-45% -$9.22K ﹤0.01% 930
2024
Q1 		$22.2K Buy
+5,500
New +$21.5K 0.01% 948

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Point72 Asia (Singapore)'s AVIR Position: Q3 2025 in Review

Point72 Asia (Singapore) opened a new position in Atea Pharmaceuticals (AVIR) in Q3 2025: 3,601 shares worth $10.4K. The stake represents ﹤0.01% of the portfolio and ranks #775 among its holdings. This is a return to the name: Point72 Asia (Singapore) previously reported a position in AVIR as recently as Q2 2024.

Point72 Asia (Singapore) first reported a position in AVIR in Q1 2024 and has held it in 3 quarters since. The position peaked at $22.2K in Q1 2024. 115 funds tracked by Wall St. Rank hold AVIR as of Q3 2025.

  • Point72 Asia (Singapore) held 3,601 shares of Atea Pharmaceuticals worth $10.4K as of Q3 2025.
  • Atea Pharmaceuticals was a new Point72 Asia (Singapore) position in Q3 2025.
  • Atea Pharmaceuticals made up ﹤0.01% of Point72 Asia (Singapore)'s portfolio in Q3 2025, its #775 holding.
  • Point72 Asia (Singapore) first reported a position in Atea Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • Point72 Asia (Singapore)'s Atea Pharmaceuticals position peaked at $22.2K in Q1 2024.
  • 115 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q3 2025, filed 14 Nov 2025.